Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 3(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05220397Phase 3Terminated

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

Role: lead

NCT00670774Phase 1Completed

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

Role: lead

NCT01349595Phase 2Terminated

Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Role: lead

All 3 trials loaded